Bone marrow transplantation for severe aplastic anemia: The Barcelona Hospital Clinic experience

Haematologica

Volumn 84, Issue 1, 1999, Pages 26-31

  Hernández Boluda, Juan Carlos ^a   Marín, Pedro ^d   Carreras, Enric ^a   Aguilar, Josep Lluis ^d   Grañena, Alberto ^a,b   Rozman, Ciril ^a   Montserrat, Emili ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DURAN I REYNALS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d NONE

Author keywords

Bone marrow transplantation; Severe aplastic anemia; Treatment

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN; IMMUNOGLOBULIN; METHOTREXATE; PENTAMIDINE;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DONOR; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE IRRADIATION; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; SIBLING; SPAIN; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CARCINOMA, SQUAMOUS CELL; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NUCLEAR FAMILY; SPAIN; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0345465961     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood 1995; 85:3367-77.
2. Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Haematologica 1994; 79:438-44.
3. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA Working Party. Br J Haematol 1988; 70:177-82.
4. Doney K, Pepe M, Storb R, et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. Blood 1992; 79:2566-71.
5. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment : a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993; 85:371-7.
6. Najean Y, Haguenauer O. Long-term (5 to 20 years) evolution of nongrafted aplastic anemias. Blood 1990; 76:2222-8.
7. Tichelli A, Gratwohl A, Nissen C, et al. Late clonal complications in severe aplastic anemia. Leuk Lymphoma 1994; 12:167-75.
8. Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 1995; 85:283-90.
9. Storb R. Bone marrow transplantation for aplastic anemia. In: Forman SJ, Blume KG, Thomas DE, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publ.; 1994. p. 583-94.
10. Doney K, Leisenring W, Storb R, et al. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 1997; 126:107-15.
11. Gluckman E, Socie G, Devergie A, et al. Bone marrow transplantation in 107 patients with severe aplastic anemia using cycloptiosphamide and thoracoabdominal irradiation for conditioning: long-term follow-up. Blood 1991; 78:2451-5.
12. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens in outcome. Blood 1992; 79:269-75.
13. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993; 329:1152-7.
14. Storb R, Prentice RL, Buckner D, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. N Engl J Med 1983; 308:302-27.
15. Niederwieser D, Pepe M, Storb R, et al. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia. Br J Haematol 1988; 69:23-8.
16. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68:119-25.
17. McCann SR, Bacigalupo A, Gluckman E, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994; 13:233-7.
18. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48:63-70.
19. Rozman C, Carreras E, Sierra J, et al. Trasplante de progenitures hemopoyéticos : 20 años de experiencia en la Escuela de Hematología "Farreras-Valentí"/Hospital Clínic de Barcelona. Med Clin (Barc) 1997; 108:681-6.
20. Prieto JM, Saez R, Carreras E, et al. Physical and phychosocial functioning of 117 survivors on bone marrow transplantation. Bone Marrow Transplant 1996; 17:1133-42.
21. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73:606-13.
22. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow HLA-matched sibling donors. Transplantation 1974; 18:295-301.
23. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75:2459-64.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
25. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972; 135:185-206.
26. Rozman C, Grañena A, Marín P, et al. Trasplante medular alogénico en aplasia medular grave. Factores determinantes del resultado en una serie de 27 casos consecutives. Med Clin (Bare) 1985; 84:129-34.
27. Sobocinski KA, Horowitz MM, Rowlings PA, et al. Bone marrow transplantation-1994: A report from the International Bone Marrow Transplant Registry. J Hematother 1994; 3:95-102.
28. Gale RP, Bortin MM, van Bekkum, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67:397-406.
29. Deeg HJ, Self S, Storb R, et al. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood 1986; 68:1363-8.
30. Stratford-May W, Sensenbrenner LL, Burns WH. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant 1993; 11:459-64.
31. Hows JM, Marsh JCW, Yin JL, et al. Bone marrow transplantation for severe aplastic anemia using cyclosporine: long-term follow-up. Bone Marrow Transplant 1989; 4:11-6.
32. Socié G, Henry-Amar M, Cosset JM, et al. Increased incidence of solid tumors after bone marrow transplantation for severe aplastic anemia. Blood 1991; 78:277-9.
33. Deeg HJ, Socié G, Schoch G, et al. Malignancies after bone marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87:386-92.